trifluridine has been researched along with Chemotherapy-Induced Febrile Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enomoto, M; Ishizaki, T; Kasahara, K; Katsumata, K; Kawakita, H; Matsudo, T; Mazaki, J; Nagakawa, Y; Shigoka, M; Tsuchida, A | 1 |
| Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T | 1 |
1 trial(s) available for trifluridine and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Survival Analysis; Thymine; Treatment Outcome; Trifluridine | 2021 |
1 other study(ies) available for trifluridine and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Pyrrolidines; Thymine; Trifluridine; United States; Uracil | 2016 |